161 related articles for article (PubMed ID: 22572723)
1. Adjuvant therapy of gastrointestinal stromal tumors.
Koshenkov VP; Rodgers SE
Curr Opin Oncol; 2012 Jul; 24(4):414-8. PubMed ID: 22572723
[TBL] [Abstract][Full Text] [Related]
2. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Le Cesne A; Blay JY; Reichardt P; Joensuu H
Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
[TBL] [Abstract][Full Text] [Related]
3. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
Blay JY
Cancer Treat Rev; 2011 Aug; 37(5):373-84. PubMed ID: 21195552
[TBL] [Abstract][Full Text] [Related]
4. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
[TBL] [Abstract][Full Text] [Related]
5. Second line therapies for the treatment of gastrointestinal stromal tumor.
Joensuu H
Curr Opin Oncol; 2007 Jul; 19(4):353-8. PubMed ID: 17545799
[TBL] [Abstract][Full Text] [Related]
6. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
7. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
8. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
9. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
14. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
[No Abstract] [Full Text] [Related]
15. Perioperative treatment of gastrointestinal stromal tumors.
Fernandes Gdos S; Blanke CD; Freitas D; Guedes R; Hoff PM
Oncology (Williston Park); 2009 Jan; 23(1):54-61. PubMed ID: 19283922
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
Steinert DM; McAuliffe JC; Trent JC
Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
[TBL] [Abstract][Full Text] [Related]
17. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Montemurro M; Bauer S
Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Shen L
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
[No Abstract] [Full Text] [Related]
19. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
20. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH
J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
